Reportstack

PharmaPoint: Type 2 Diabetes - Italy Drug Forecast and Market Analysis to 2022

 

Naperville, IL -- (SBWIRE) -- 11/21/2013 -- Reportstack, provider of premium market research reports announces the addition of PharmaPoint: Type 2 Diabetes - Italy Drug Forecast and Market Analysis to 2022 market report to its offering
PharmaPoint: Type 2 Diabetes - Italy Drug Forecast and Market Analysis to 2022

Summary

The publisher has released its new Country report, PharmaPoint: Type 2 Diabetes - Italy Drug Forecast and Market Analysis to 2022. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. In the emerging markets in particular, uptake of branded drugs will increase due to rapid economic growth. We anticipate that the type 2 diabetes market will not experience a fundamental shift in the classes of drugs that are preferred by physicians. Rapid uptake of drugs from the novel class of SGLT-2 inhibitors will occur; however, DPP-4 inhibitors and GLP-1 receptor agonists will continue dominating the noninsulin type 2 diabetes space. GLP-1 receptor agonists will experience the fastest growth of all classes (CAGR of 17%), due to their weight-loss effects and their novel once-weekly administration, which is preferable to the standard once- or twice-daily therapies.

As in the global market, this growth will be fueled by the dramatic increase in the prevalence and diagnosis of the disease as well as by the uptake of new branded drugs. A dip in sales caused by Actos patent expiry in 2012 and three insulin products patent expiries by 2015 will be offset by 16 pipeline product launches over the forecast period. Byettas patent expiration in 2016 will not have a major impact on the market as its sales have been declining, with Victoza and Bydureon overtaking its shares.

Scope

- Overview of type 2 diabetes including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Italy including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Italy from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting Italy type 2 diabetes market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Italy

To view the table of contents for this market research report please visit
http://www.reportstack.com/product/146566/pharmapoint-type-2-diabetes-italy-drug-forecast-and-market-analysis-to-2022.html
Contact:
Roger Campbell
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###